Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exact Sciences Corp EXAS

Healthcare Biotechnology
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test... see more

Recent & Breaking News (NDAQ:EXAS)

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024

Business Wire May 7, 2024

Exact Sciences to Participate in May Investor Conference

Business Wire May 1, 2024

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

Business Wire April 15, 2024

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes

Business Wire April 11, 2024

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

Business Wire April 8, 2024

Exact Sciences Schedules First Quarter 2024 Earnings Call

Business Wire April 8, 2024

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

Business Wire April 4, 2024

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Business Wire March 28, 2024

Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner

Business Wire March 27, 2024

The New England Journal of Medicine Publishes Cologuard Plus(TM) Test Results from Pivotal BLUE-C Study

Business Wire March 13, 2024

Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer

Business Wire March 7, 2024

Exact Sciences to Participate in March Investor Conference

Business Wire February 26, 2024

Exact Sciences Announces Fourth Quarter 2023 Results

Business Wire February 21, 2024

Exact Sciences Schedules Fourth Quarter 2023 Earnings Call

Business Wire February 1, 2024

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

PR Newswire January 7, 2024

Exact Sciences to participate in J.P. Morgan Healthcare Conference

PR Newswire January 2, 2024

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

PR Newswire December 7, 2023

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

PR Newswire November 30, 2023

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

PR Newswire November 17, 2023

Exact Sciences Announces Third-Quarter 2023 Results

PR Newswire November 1, 2023